Therakind is attending BIO Europe 2024
London, England – October 2024 – Therakind Limited (“Therakind”), a specialty pharmaceutical company focused on developing and delivering niche medicines, is attending BIO 2024 in Stockholm between 4th and 6th of November. BIO is a large conference attracting around 6,000 attendees from various aspects of the life science industry.
Therakind has a portfolio of dry powder intranasal devices and expertise in formulation development and regulatory strategy. Its DriDose® innovative dry powder nasal delivery device range is designed to incorporate various types of pharmaceutical candidates. The technology includes both single-use and reusable versions, each capable of being modified to accommodate different powder-loading capacities. The reusable device is designed to reduce plastic waste associated with single-use devices and injections.
Our primary aim for BIO 2024 is to seek partnership opportunities for the development of dry powder nasal candidates using the DriDose® technology. Additionally, we are seeking partners to advance a novel antimicrobial candidate with promising preclinical data.
If you are interested in learning more about the DriDose® technology, please reach out to arrange a meeting through the BIO platform:
https://partneringone.informaconnect.com/event/774/profile/user/2233/company/1260
For those interested in partnering with Therakind outside BIO, please contact us at bd@therakind.com
For more information, please contact:
Therakind Ltd
Dr Susan Conroy, Chief Executive Officer
Tel: ++44 (0) 208 346 603
Email: info@therakind.com
Website: www.therakind.com
About Therakind Limited
Therakind is a specialty pharmaceutical company with a proprietary and partnered pipeline focused on improving medicine adherence through more patient-friendly dosing options. We have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to incorporate the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. To date, we have developed and obtained marketing authorisations for three products and our intranasal device for the delivery of a dry powder drug formulation, DriDose®, is available for co-development.
To find out more, please visit www.therakind.com